ASX Share rice
Tue 11 Aug 2020 - 11:08:am (Sydney)

ATH Share Price

ALTERITY THERAPEUTICS LIMITEDATHPharmaceuticals, Biotechnology & Life Sciences

ATH Company Information

Name:

Alterity Therapeutics Limited

Sector:

Healthcare

Industry:

Biotechnology

Address:

460 Bourke Street Melbourne VIC Australia 3000

Phone:

61 3 9349 4906

Full Time Employees:

14

Co-Founder, Exec. Chairman, CEO & MD:

Mr. Geoffrey Paul Kempler

Chief Financial Officer:

Ms. Kathryn J. E. Andrews

Chief Medical Officer & Sr. VP of Clinical Devel.:

Dr. David A. Stamler

Chief Scientific Advisor and Member of R&D Advisory Board:

Dr. Rudolph Emile Tanzi

Chief Medical Advisor:

Dr. Steven D. Targum

Company Overview:

Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidates include PBT434 that is in Phase I clinical trial for the treatment of Parkinson's disease and other movement disorders. It is also developing PBT2 for patients with Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. The company was founded in 1997 and is based in Melbourne, Australia.

ATH Share Price Information

Shares Issued:

1.08B

Market Capitalisation:

$67.27M

Revenue (TTM):

$4.38M

Revenue Per Share (TTM):

$0.01

Earnings per Share:

$-0.02

Profit Margin:

-2.8855

Operating Margin (TTM):

$-2.96

Return On Assets (TTM):

$-0.57

Return On Equity (TTM):

$-1.14

Quarterly Revenue Growth (YOY):

-0.235

Gross Profit(TTM):

$4.63M

Diluted Earnings Per Share (TTM):

$-0.016

ATH CashFlow Statement

CashFlow Date:

2020-06-30

Dividends Paid:

$0

Capital Expenditures:

$0

ATH Income Statement

Income Date:

2019-06-30

Income Before Tax:

$-12,337,830

Net Income:

$-12,337,830

Gross Profit:

$4.63M

Operating Income:

$-12,231,832

Other Operating Expenses:

$132.97K

Total Revenue:

$108.54K

Total Operating Expenses:

$12.34M

Cost Of Revenue:

$322.10K

ATH Balance Sheet

Balance Sheet Date:

2019-06-30

Total Liabilities:

$3.36M

Total Stockholder Equity:

$16.55M

Other Current Liabilities:

$11.72K

Total Assets:

$19.91M

Common Stock:

$156.63M

Other Current Assets:

$10.03K

Retained Earnings:

$-141,236,838

Other Liabilities:

$34.98K

Cash:

$14.40M

Total Current Liabilities:

$3.32M

Property - Plant & Equipment:

$48.75K

Net Tangible Assets:

$16.55M

Total Current Assets:

$19.86M

Net Receivables:

$4.83M

Short-Term Investments:

$48.75K

Accounts Payable:

$1.69M

Non Currrent Assets (Other):

$48.75K

Short-Term Investments:

$48.75

Non Current Liabilities Total:

$34.98K

ATH Share Price History

ATH News

05 Aug, 2020
Alterity Therapeutics (NASDAQ: ATHE) shares are trading lower on Wednesday.This is a potential sell-off after the stock increased over 200% yesterday following the company announcing it will present at two upcoming conferences and is expected to report positive data for its treatment for Parkinson's Disorder MSA.Alterity Therapeutics is engaged in research collaboration with Takeda for the treatment of Parkinson's disease gastrointestinal neuropathology. The company's lead drug candidate-PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. It has also advanced a drug candidate for Parkinson's disease and other movement disorders (PBT434) and brain cancer (PBT519), which are in preclinical toxicology testing.Alterity Therapeutics shares were trading down 15.47% to $2.90 at time of publication on Wednesday. The stock has a 52-week high of $5.15 and a 52-week low of 28 cents.See more from Benzinga * Why Alterity's Stock Is Trading Higher Today * Why Alterity Therapeutics Stock Is Trading Higher Today(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
04 Aug, 2020
Shares of Alterity Therapeutics Ltd. nearly tripled (up 173%) toward a 3-year high on heavy volume in premarket trading Tuesday, after the therapeutic drugs developer said it will present positive data for its lead drug candidate ATH434 for the treatment of multiple system atrophy (MSA), a Parkinsonian disorder. Trading volume ballooned to 8.3 million shares, already more than double the full-day average of 3.5 million shares. The company said new animal data confirm and extend previous finding that demonstrated ATH434 reduced pathology, preserved neurons and improved motor performance. The company said it has been selected to present at the 2020 International Congress of Parkinson's Disease and Movement Disorders, and the American Neurological Association's 2020 Annual Meeting. Alterity said it will also present cardiac safety data from its Phase 1 study of ATH434. The stock has run up 73.1% year to date through Monday, while the S&P 500 has gained 2.0%.
The shares of Alterity Therapeutics Ltd. (NASDAQ: ATHE) advanced in the after-hours session trading in New York on Monday and in the regular session in Sydney on Tuesday.What Happened: The surge came as Alterity Therapeutics reported positive data from an animal testing of ATH434 — its leading drug candidate for Multiple System Atrophy, a Parkinsonian disorder.The new data "independently confirm and extend previous findings demonstrating that ATH434 reduces α-synuclein pathology, preserves neurons, and improves motor performance," Alterity Therapeutics noted.Why It Matters: The Melbourne-based pharmaceutical company in June said it had reached an agreement with the United States Food and Drug Administration on the non-clinical investigations required to support the second phase of its clinical trial of ATH434.The FDA had also agreed on the company's design for the Phase 2 study, it claimed.What's Next: Alterity Therapeutics noted that the data from the latest study will be presented at the 2020 International Congress of Parkinson's Disease and Movement Disorders in September and at the American Neurological Association's 2020 Annual Meeting in October.Price Action: The company's shares closed 38.24% up at $0.034 in Sydney on Tuesday, with an intraday high of $0.041.Alterity Therapeutics shares closed 10.37% higher at $1.49 in the after-hours session in New York on Monday. See more from Benzinga * Prescription Drug Prices Tracker, Telehealth Platform GoodRx Files For IPO: Report * Huawei Becomes The World's Largest Smartphone Supplier As China Sales Remain High During Pandemic * Tesla Under Probe In South Korea For Supposed Issues With Autopilot, Other Braking, Steering Systems(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") today announced that new clinical and experimental pharmacology data for its lead drug candidate ATH434 (formerly PBT434) has been selected for presentation at the 2020 International Congress of Parkinson's Disease and Movement Disorders (MDS 2020) and the American Neurological Association's 2020 Annual Meeting (ANA 2020).
30 Jul, 2020
Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") releases its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 31 July 2020 (Q4 FY20).
01 Jul, 2020
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 30) * ADC Therapeutics SA (NYSE: ADCT) * Akebia Therapeutics Inc (NASDAQ: AKBA) * Alterity Therapeutics Ltd (NASDAQ: ATHE) (announced agreement with the FDA regarding Phase 2 study of Parkinsonian disorder drug) * Calliditas Therapeutics AB ADR (NASDAQ: CALT) * GENMAB A/S/S ADR (NASDAQ: GMAB) - partner Seattle Genetics, Inc. (NASDAQ: SGEN) announced positive results for antibody-drug conjugate for cervical cancer * Halozyme Therapeutics, Inc. (NASDAQ: HALO) * Hologic, Inc. (NASDAQ: HOLX) (reacted to a positive analyst action) * Legend Biotech Corp (NASDAQ: LEGN) * Meridian Bioscience, Inc. (NASDAQ: VIVO) * Mersana Therapeutics Inc (NASDAQ: MRSN) * Novavax, Inc. (NASDAQ: NVAX) * Opko Health Inc. (NASDAQ: OPK) * Pacira Biosciences Inc (NASDAQ: PCRX) * Pliant Therapeutics Inc (NASDAQ: PLRX) * ResMed Inc. (NYSE: RMD) * Tandem Diabetes Care Inc (NASDAQ: TNDM) * Twist Bioscience Corp (NASDAQ: TWST) (announced launch of Twist Respiratory Virus Research Panel for detecting a range of respiratory diseases) * West Pharmaceutical Services Inc. (NYSE: WST)Down In The Dumps (Biotech Stocks Hitting 52-week Lows June 30) * Brickell Biotech Inc (NASDAQ: BBI) * Iterum Therapeutics PLC (NASDAQ: ITRM) (announced $5-million registered offering) * Qualigen Therapeutics Inc (NASDAQ: QLGN) * Sonnet Biotherapeutics Holdings Inc (NASDAQ: SONN) * VIVUS, Inc. (NASDAQ: VVUS)Stocks In Focus T2 Biosystems Pre-Announces In-Line Q2 Revenues, Launches COVID-19 Test In US T2 Biosystems Inc (NASDAQ: TTOO) announced the U.S. launch of the T2SARS-CoV-2 Panel, its COVID-19 molecular diagnostic test.The test was developed under a license agreement with the Center of Discovery and Innovation at Hackensack Meridian Health and is being commercially distributed after meeting requirements for an Emergency Use Authorization request to the FDA.Separately, the company pre-announced second-quarter results and said it expects revenues of $2.4 million to $2.6 million versus $1.8 million in the year-ago period, while analysts estimate revenues of $2.45 million.The stock was surging 74.8% to $2.22 premarket Wednesday.Akero Reports Positive Results For Midstage NASH Drug Study Akero Therapeutics Inc (NASDAQ: AKRO) announced positive results from a 16-week analysis of secondary and exploratory endpoints in its Phase 2a BALANCED study of efruxifermin in patients with nonalcoholic steatohepatitis.The company said of the 40 treatment responders who had end-of-treatment biopsies, 48% achieved at least a one-stage improvement in fibrosis without worsening of NAFLD activity score and 28% achieved at least a two-stage improvement in fibrosis.In addition, 48% of responders achieved NASH resolution with no worsening of fibrosis. Treatment with EFX was generally reported to be well-tolerated, Akero said.The stock was up 45.26% at $36.20 premarket Wednesday.See also: The Week Ahead In Biotech (June 28- July 4): Pending Clinical Readouts In Focus During A Short Holiday Week Pfizer, Germany's Merck KGaA Announce FDA Nod For Label Expansion For Cancer Drug Pfizer Inc. (NYSE: PFE) and MERCK KGAA/S ADR (OTC: MKKGY) unit EMD Serono said the FDA approved the sBLA for Bavencio for the maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma that has not progressed with first-line platinum-containing chemotherapy.Aravive To Join Russell 2000, 3000 Indexes Aravive Inc (NASDAQ: ARAV) said it has been added to the Russell 2000 and Russell 3000 indexes, effective June 29, as part of the 2020 Russell U.S. indexes reconstitution. The stock added 7.39% to $12.50 in after-hours trading.BeiGene Begins Commercialization of Amgen's Bone Tumor Drug In China Beigene Ltd (NASDAQ: BGNE) said it has begun commercializing Amgen, Inc.'s (NASDAQ: AMGN) Xgeva (denosumab) in China for the treatment of giant cell tumor of bone. This marks the first Amgen product that has been transitioned to BeiGene for commercialization in China since the commencement of the parties' global strategic oncology collaboration in January 2020, Beigene said.Matinas Announces Resumption Of Clinical Studies Following COVID-Induced Pause Matinas BioPharma Holdings Inc (NYSE: MTNB) said it has commenced enrollment and started dosing patients in the ENHANCE-IT study, a head-to-head study of MAT9001 vs. Vascepa.The company expects enrollment to be completed by August and top-line data from the study to be available in the first quarter of 2021.View more earnings on IBBThe company also said it expects to resume dosing patients in the EnACT study imminently, following the recent receipt of necessary governmental and regulatory approvals in Uganda.Both studies temporarily paused enrollment in March due to the COVID-19 pandemic.In premarket trading Wednesday, the stock was adding 3.49% to 80 cents.Earnings Avid Bioservices Inc's (NASDAQ: CDMO) fourth-quarter revenue fell 26% to $12.6 million and the loss per share widened from 2 cents to 11 cents.Analysts had expected a wider loss of 16 cents per share.The company guided fiscal year 2021 revenues to a range of $76 million to $81 million against an $83.85-million consensus estimate.In after-hours trading, the stock advanced 5.56% to $6.93.Offerings Chiasma Inc (NASDAQ: CHMA), which recently received FDA approval for Mycapssa for the treatment of acromegaly, said it has commenced an underwritten public offering of its common stock, and to certain investors, pre-funded warrants to purchase shares of its common stock.All of the securities to be sold in the offering are to be sold by the company. The company said it intends to use the net proceeds primarily for the commercialization of Mycapssa.The stock slipped 14.50% to $4.60 in after-hours trading.Transenterix Inc (NYSE: TRXC) said it has commenced an underwritten offering of common stock. The stock was down 29.78% to 38 cents premarket. Related Link: Gilead Announces Pricing Of Coronavirus Treatment Remdesivir: 'We Believe All Patients Will Have Access'See more from Benzinga * Inovio Analyst Downgrades COVID-19 Vaccine Developer, Says Risk Higher After Rally(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
30 Jun, 2020
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") is pleased to announce that it has received guidance from the US Food and Drug Administration (FDA) in relation to the development pathway for ATH434 (previously PBT434), the company's lead compound for the treatment of Multiple System Atrophy (MSA), a Parkinsonian disorder.
30 Apr, 2020
Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") releases its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 31 March 2020 (Q3 FY20).
21 Apr, 2020
In 2005, Geoffrey Kempler was appointed CEO of Alterity Therapeutics Limited (ASX:ATH). This analysis aims first to...
22 Feb, 2020
It's nice to see the Alterity Therapeutics Limited (ASX:ATH) share price up 12% in a week. But spare a thought for the...
07 Feb, 2020
Alterity Therapeutics Limited (ASX:ATH, NASDAQ:ATHE) has received notification from the Listing Qualifications Department of NASDAQ advising the Company that it is currently non-compliant with NASDAQ's requirement that listed securities maintain a minimum bid price of $US1.00 per share on NASDAQ as outlined in the NASDAQ Listing Rules.
12 Nov, 2019
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
13 Sep, 2019
In 2005 Geoffrey Kempler was appointed CEO of Alterity Therapeutics Limited (ASX:ATH). This report will, first...